Intracranial And Systemic Atherosclerosis In The Navigate Esus Trial: Recurrent Stroke Risk And Response To Antithrombotic Therapy
Journal of Stroke and Cerebrovascular Diseases(2020)
摘要
East Asia region was the strongest factor associated with intracranial atherosclerosis. There were no statistically significant differences between rivaroxaban and aspirin prophylaxis for recurrent ischemic stroke in patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis.
更多查看译文
关键词
Embolic stroke,ESUS,Rivaroxaban,Cerebrovascular atherosclerosis,Intracranial atherosclerosis,Randomized trial
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络